PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Website: http://www.ptcbio.com/
606 articles about PTC Therapeutics, Inc.
-
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2023.
-
PTC Therapeutics to Participate at Upcoming March 2024 Investor Conferences
2/27/2024
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 22, 2024
2/22/2024
PTC Therapeutics, Inc. announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,840 shares of its common stock and 4,275 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to six new employees.
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
2/15/2024
PTC Therapeutics, Inc. announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.
-
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
1/25/2024
PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion following the re-examination procedure for the conditional marketing authorization of Translarna™.
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
1/8/2024
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare Conference today, Monday, January 8, at 10:30am EST/7:30am PST.
-
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8 , at 7:30 a.m. PST / 10:30 a.m. EST.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 14, 2023
12/14/2023
PTC Therapeutics, Inc. announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an aggregate of 3,575 shares of its common stock and 3,035 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to two new employees.
-
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
12/5/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 03, 2023
11/3/2023
PTC Therapeutics, Inc. announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and 19,125 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 21 new employees.
-
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
10/26/2023
PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2023.
-
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
10/19/2023
PTC Therapeutics, Inc. announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty stream.
-
The deal with PTC Therapeutics increases Royalty Pharma’s stake to 13% of total royalties garnered by Evrysdi, the blockbuster drug for spinal muscular atrophy licensed and marketed by Roche.
-
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results
10/16/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m. ET.
-
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
9/28/2023
PTC Therapeutics, Inc. announced further strategic prioritization and associated workforce reduction.
-
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
9/15/2023
PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy.
-
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
9/7/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy.
-
PTC Therapeutics to Participate at Upcoming September 2023 Investor Conferences
8/30/2023
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.
-
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
8/28/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 which is being held from Aug. 29 to Sept. 1 in Jerusalem, Israel.
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
8/3/2023
PTC Therapeutics, Inc. announced a corporate update and financial results for the second quarter ending June 30, 2023.